Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06441669
Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT
Sponsor: Anhui Provincial Hospital
View on ClinicalTrials.gov
Summary
To explore the effect of letermovir prophylaxis on cytomegalovirus-specific immune reconstitution post unrelated cord blood transplantation
Official title: Effect of Letermovir Prophylaxis on Cytomegalovirus-specific Immune Reconstitution Post Unrelated Cord Blood Transplantation
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2024-05-01
Completion Date
2026-05-20
Last Updated
2024-06-04
Healthy Volunteers
No
Conditions
Interventions
DRUG
Letermovir
Patients will be given Letermovir with a recommended dose from +1 day to +100 days after UCBT.
Locations (1)
Anhui Provincial Hospital
Hefei, Anhui, China